Open AccessFirst‐in‐man allopregnanolone use in super‐refractory status epilepticus
Author(s) -
Vaitkevicius Henrikas,
Husain Aatif M.,
Rosenthal Eric S.,
Rosand Jonathan,
Bobb Wendell,
Reddy Kiran,
Rogawski Michael A.,
Cole Andrew J.
Publication year - 2017
Publication title -
annals of clinical and translational neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.824
H-Index - 42
ISSN - 2328-9503
DOI - 10.1002/acn3.408
Subject(s) - allopregnanolone , medicine , status epilepticus , neuroactive steroid , refractory (planetary science) , desensitization (medicine) , gabaa receptor , neuroscience , neuroprotection , receptor , epilepsy , psychiatry , psychology , biology , astrobiology
Super‐refractory status epilepticus ( SRSE ) is associated with high morbidity and mortality. Treatment of SRSE is complicated by progressive cortical hyperexcitability believed to result in part from synaptic GABA receptor internalization and desensitization. Allopregnanolone, a neurosteroid that positively modulates synaptic and extrasynaptic GABA A receptors, has been proposed as a novel treatment. We describe the first two patients with SRSE who were each successfully treated with a 120‐h continuous infusion of allopregnanolone. Both patients recovered from prolonged SRSE with good cognitive outcomes.